Non-Hodgkin's Lymphoma News

FDA Approves Yescarta?, Revolutionary CAR-T Immunotherapy for Non-Hodgkin's Lymphoma Patients - PR Newswire (press release)



Genetic Literacy Project
 
FDA Approves Yescarta?, Revolutionary CAR-T Immunotherapy for Non-Hodgkin's Lymphoma Patients 
PR Newswire (press release)
TAMPA, Fla., Oct. 18, 2017 /PRNewswire-USNewswire/ -- The Food and Drug Administration announced today the approval of Yescarta? (Axicabtagene ciloleucel), a revolutionary new immunotherapy for adult patients with diffuse large B cell lymphoma, ...
Gene therapy that reboots body's immune cells to fight non-Hodgkin's lymphoma approved by FDA Genetic Literacy Project
FDA Approves Yescarta, First CAR T-Cell Therapy for Lymphoma Managed Care magazine
'Revolution in cancer medicine': KU joins fight with approval of this therapy Kansas City Star
Chicago Tribune  -MedPage Today  -FDA.gov  -gilead.com 
all 205 news articles » 


Wash U Medical Center offers new gene-altering treatment for some ... - St. Louis Public Radio



St. Louis Public Radio
 
Wash U Medical Center offers new gene-altering treatment for some ... 
St. Louis Public Radio
Washington University's Siteman Cancer Center offers patients with certain blood cancers a new gene-altering therapy that uses the immune system to attack ...

and more » 


Validea Warren Buffett Strategy Daily Upgrade Report - 10/24/2017 - Nasdaq



Validea Warren Buffett Strategy Daily Upgrade Report - 10/24/2017 
Nasdaq
It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for ...

and more » 


Doctors Say New Cancer Treatment Might Even Be Cure « CBS ... - CBS New York



CBS New York
 
Doctors Say New Cancer Treatment Might Even Be Cure « CBS ... 
CBS New York
NEW YORK (CBSNewYork) ? Doctors say a new treatment for Non-Hodgkin's lymphoma might even be a cure. The treatment uses a patient's own immune ...

and more » 


Immune Design Announces G100's Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non ... - GlobeNewswire (press release)



Immune Design Announces G100's Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non ... 
GlobeNewswire (press release)
G100 has also been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of follicular non-Hodgkin's lymphoma. G100 is a product candidate from Immune Design's GLAAS® discovery platform. It contains a potent ...

and more » 


CAR T-cells Targeting CD20-positive Non-Hodgkin's Lymphoma Safe and Effective, Long-term Study Shows - Lymphoma News Today



Lymphoma News Today
 
CAR T-cells Targeting CD20-positive Non-Hodgkin's Lymphoma Safe and Effective, Long-term Study Shows 
Lymphoma News Today
A long-term follow-up study of immunotherapy with CAR T-cells in patients with B-cell non-Hodgkin's lymphoma with CD20-carrying B-cells show the approach is similar in effectiveness and safety to the more common CAR T-cell therapy. The study, published ...

 


Predators: 3 things to watch this week - The Tennessean



The Tennessean
 
Predators: 3 things to watch this week 
The Tennessean
Every morning during the Predators' season, "Morning Skate" will highlight the odds and ends surrounding the team. Consider this a one-stop shop for Predators-related information. The Predators play three games this week, so here's what to watch in each:.

 


AstraZeneca helps ADCT to $200M megaround to push anticancer ... - FierceBiotech



FierceBiotech
 
AstraZeneca helps ADCT to $200M megaround to push anticancer ... 
FierceBiotech
ADC Therapeutics has raised $200 million (?170 million), bringing its total haul up to $455 million. The antibody-drug conjugate (ADC) specialist will use the ...

and more » 


French Researchers Develop Quick, Cost-Effective Test to Detect DLBCL Subtypes - Lymphoma News Today



Lymphoma News Today
 
French Researchers Develop Quick, Cost-Effective Test to Detect DLBCL Subtypes 
Lymphoma News Today
DLBCL is the most common non-Hodgkin's lymphoma subtype. Depending on the cell from which the disease originates, DLBCL can be classified into germinal center B-cell-like, activated B-cell-like, and primary mediastinal B-cell lymphoma. Because each ...

 


Day with Islanders a 'dream come true' for LI boy with cancer ... - Newsday



Newsday
 
Day with Islanders a 'dream come true' for LI boy with cancer ... 
Newsday
Brandon Bloom, 8, of South Setauket, was diagnosed with Stage 4 non-Hodgkin's lymphoma in April 2016, and has been undergoing chemotherapy.
New York Islanders Welcome Brandon Bloom To Team Practice Eyes on Isles
Ailing boy becomes a New York Islander for a day - Story | WNYW Fox5NY

all 6 news articles »